Inovio Pharma (INO)
$11.38
0.03 (0.26%)
INO Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
1.04B
PE Ratio
-9.98
EPS
-1.14
Volume (Avg. Vol.)
638
Day's Range
11.35 - 11.35
52-Week Range
2.09 - 33.79
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
Why the FDA’s Inquiry of Inovio Is More Critical Than You Think
INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.
Avoid Inovio Like the Plague After Its 64% Price Drop
INO stock has fallen more than 60% since June and further declines look imminent as the company struggles with its Covid-19 vaccine.
Inovio Stock Is a Great Long Setup for an Overreaction Trade
A freak-out ensued after the FDA placed a halt on Inovio's Covid-19 vaccine trials, but the price dip is a chance to buy INO stock cheaper.
Avoid Inovio Pharmaceuticals Like the Plague
The pharma is pursuing a Covid-19 vaccine. But INO stock is risky as the company has failed to bring a product to market for 40 years.
Inovio Pharmaceuticals Does Not Need Any More Misfortune
INO stock is plummeting after the FDA put a hold on its INO-4800 vaccine candidate. But by the time Inovio resumes the trial, will a vaccine be needed?
Don’t Count Out Inovio Pharmaceuticals Stock Just Yet
INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA.
Trump Coronavirus News: Why the Market Is Sliding Today
The market is sliding on today on Trump coronavirus news following confirmation that President Donald Trump tested positive.
This Latest FDA Hold Is a Crushing Blow for Reeling Inovio Stock
Inovio has lost the race for a novel coronavirus vaccine. And INO stock could plummet, given increasing doubts about the company as a whole.
How to Decide if Inovio Is a Buy After Its 28% Correction
Inovio Pharmaceuticals fell 28% after the FDA put a partial clinical hold on vaccine trial. Should you buy INO stock on the dip?
All Hope Is Not Lost for Inovio Pharmaceuticals Stock
Trends come and trends go, but INO stock is coming back but innovation never goes out of style. Hold on trials hurts, but doesn't kill yet.
Inovio Pharmaceuticals News: INO Stock Slammed 28% by Pause in Covid-19 Vaccine Trial
Inovio Pharmaceuticals (INO) news for Monday includes the pausing of its vaccine trial for the novel coronavirus sending INO stock lower.
Inovio Stock Still Has Real Promise Despite Faltering in Vaccine Race
INO stock lost steam due to delays in the next stage of its vaccine trials, but there are plenty of reasons why it's still a worthwhile bet.
Speculate on Inovio and Covid-19 Vaccine Developers
After bottoming at $10 earlier this month, investor interest soared in the last week for INO stock and the company's DNA medicine.
Inovio Stock May Very Well Be the Long Shot Vaccine Gamble Worth Taking
Inovio's DNA-based approach gives potential advantages to its Covid-19 vaccine candidate and adds fuel to the volatility of INO stock.
DNA Vaccine Gives Inovio Pharmaceuticals Stock a Long Shelf Life
INO stock traders may be skeptical about Inovio's main Covid-19 vaccine candidate, but the CEO made a convincing case to stay in the trade.
The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals
Although vaccine plays are inherently risky, the recent robust rally in INO stock is backed by strong and compelling science.
5 Top Stock Trades for Friday: TWLO, MU, F, INO, X
Twilio, Micron, Ford, Inovio and U.S. Steel were our top stock trades for Friday. So, let's have a look at the charts to see what's new.
At This Point, There’s No Reason to Buy (or Dump) Inovio Pharmaceuticals Stock
Curious why INO stock jumped in recent trading? Overall optimism wasn't the only reason. Read on to gain some perspective on its chances.
INO Stock: Why Inovio Pharmaceuticals Is Rallying 15% Today
Inovio Pharmaceuticals teased investors on Monday that Phase 1 results were just around the corner. INO stock is still rallying. Here's why.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
